Rab Prinjha
Director/Board Member chez Padlock Therapeutics, Inc.
Profil
Rab Prinjha is currently a Director at Padlock Therapeutics, Inc. He previously worked as the Head of Epigenetics Discovery Performance Unit at GSK Plc.
He obtained a doctorate degree from University College London.
Postes actifs de Rab Prinjha
| Sociétés | Poste | Début |
|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Anciens postes connus de Rab Prinjha
| Sociétés | Poste | Fin |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | - |
Formation de Rab Prinjha
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
